August 2012
-
MannKind Corporation announced that it is developing a DPI formulation of MNKD-1501 ralinepag for the treatment of pulmonary arterial hypertension under an agreement with United Therapeutics under a 2018 licensing and collaboration agreement between the companies that… Read more . . .
-
UK-based inhaler developer Merxin Ltd has been awarded a 2026 King’s Award for Enterprise for Innovation, the company announced. Merxin, which is headquartered in King’s Lynn, UK, was launched in 2015 . The award announcement… Read more . . .
-
Copley Scientific has announced the launch of its SRS 100i automated sample recovery system for use with delivered dose uniformity and APSD testing set-ups, including the compendial dose uniformity sample apparatus (DUSA), the Next Generation Impactor (NGI),… Read more . . .
-
3P innovation, which makes filling systems for dry powder inhaler blisters, and Mikron Automation, which offers device assembly systems, announced that they have partnered to provide integrated manufacturing systems for blister-based DPIs. The companies say that… Read more . . .
-
Insilico Medicine, which has facilities in the US and China, said that an IND for a Phase 1 PK trial of rentosertib (ISM001-055) inhalation solution has been cleared by the CDE. The company said that… Read more . . .
-
US-based Transpire Bio announced that it has opened an R&D facility in Shanghai, China with approximately 40 employees who will work on development of generic OINDPs for the UK, European, and Asian Pacific markets. Transpire… Read more . . .
-
AstraZeneca announced that the FDA has approved the company’s Breztri Aerosphere budesonide / glycopyrrolate / formoterol MDI for the treatment of asthma in patients aged 12 and older. The agency originally approved Breztri for the treatment of… Read more . . .
-
Inhaled drug developer Avalyn Pharma has announced the appointments of attorney Adam Golden as General Counsel and Head of Business Development and pharma sales and marketing veteran Frank Salisbury as Senior VP, Commercial. Golden was… Read more . . .
-
Cipla has received FDA approval of its ANDA for a generic version of Ventolin HFA albuterol MDI for the treatment of asthma, the company announced. GSK’s NDA Ventolin HFA was approved by the agency in… Read more . . .
-
Rocket Science Health announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,569,658, titled “Dual Nozzles For Insertion Into Paired Body Orifices (e.g., Nasal Passages, Etc.)” covering the company’s intranasal… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.